CIPLA LIMITED

ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.

Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.

Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.

Torrent Pharma is in advanced talks with KKR to acquire JB Chemicals and Pharmaceuticals for approximately Rs 20,734.61 crore ($2.4 billion), marking its largest acquisition to date.

• Cipla has introduced ZEMDRI (Plazomicin), a novel intravenous aminoglycoside treatment for complicated urinary tract infections (cUTI) including pyelonephritis in adult patients in India. • The drug demonstrates promising activity against multi-drug resistant bacteria, including Carbapenem-resistant Enterobacteriaceae (CRE), addressing a critical challenge in managing resistant infections in India. • ZEMDRI's approval was supported by the EPIC clinical trial, the first randomized controlled study of once-daily aminoglycoside therapy for cUTI treatment, with Cipla generating India-specific pathogen data to validate its effectiveness.

Cipla's Goa API facility and Sitec Labs' Mahape analytical testing facility have both received Voluntary Action Indicated (VAI) status from the USFDA following recent inspections.

Pulmatrix plans to divest its clinical assets including PUR3100, a Phase 2-ready inhaled treatment for acute migraine, as part of its upcoming merger with Cullgen expected to close in June 2025.

Cipla projects EBITDA margins of 23.5-24.5% for FY26 while targeting growth through GLP-1 therapies, particularly semaglutide generics launching globally as patents expire.

Cipla has received CDSCO panel approval to proceed with Phase III clinical trials for inhaled itraconazole dry powder (PUR1900) at a 40mg dose, following successful Phase II results.

Cipla has secured USFDA approval for paclitaxel protein-bound particles for injectable suspension, a generic version of Bristol Myers Squibb's Abraxane, indicated for treating multiple cancer types.